NDA 213246 · Eli Lilly and CO
Retevmo
Selpercatinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 8, 2020
Approved uses
9
Original approval plus efficacy supplements
Registered trials
37
3 Phase 3, 5 recruiting
FAERS reports
1,395
1,084 serious, 208 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 11, 2026.
RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options ( 1.4 ) 1.1 RET Fusion-Positive Non-Small Cell Lung Cancer RETEVMO ® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test. 1.2 RET -Mutant Medullary Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy. 1.3 RET Fusion-Positive Thyroid Cancer RETEVMO is indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected...
Mechanism: Selpercatinib is a kinase inhibitor. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC 50 values ranging from 0.92 nM to 67.8 nM. In other enzyme assays, selpercatinib also inhibited FGFR 1, 2, and 3 at higher concentrations that were still clinically achievable. In cellular assays, selpercatinib inhibited RET at approximately 60-fold lower concentrations than FGFR1 and 2 and approximately 8-fold lower concentration than VEGFR3. Certain point mutations in RET or chromosomal rearrangements involving in-frame fusions of RET with various...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 14, 2026 Supplement 17 · Efficacy OrphanLetterLabel
- Nov 20, 2025 Supplement 15 · Efficacy · priority review OrphanLetterLabel
- Sep 27, 2024 Supplement 13 · Efficacy · priority review OrphanLabelLetter
- Sep 27, 2024 Supplement 11 · Efficacy OrphanLabelLetterReview
- Jun 12, 2024 Supplement 9 · Efficacy OrphanLabelLetter
- May 29, 2024 Supplement 12 · Efficacy · priority review Accelerated approvalOrphanLabelLetter
- Sep 21, 2022 Supplement 7 · Efficacy OrphanLetterLabel
- Sep 21, 2022 Supplement 8 · Efficacy · priority review OrphanLetterLabelReview
- May 8, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- RETEVMO · SELPERCATINIB 40MG · CAPSULE, ORAL · Prescription
- RETEVMO · SELPERCATINIB 80MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Selpercatinib" as an intervention, any sponsor and status, largest first.
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03157128 · 857 participants · Start May 2, 2017 · Primary completion Feb 14, 2025
Drug: LOXO-292 · For: Non-Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer and 1 more
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 85 sites in all
Fudan UniversityAcademic, hospital or other
NCT06195228 · 800 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy and 4 more · For: Advanced Thyroid Cancer Patients Who Received Target Therapy
Sites: Fuzhou, China; Zhengzhou, China; Wuhan, China · 8 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruiting
Fujian Medical UniversityAcademic, hospital or other
NCT07010393 · 335 participants (planned) · Start Jul 1, 2025 · Primary completion Dec 31, 2027
Drug: Dabrafenib; Trametinib and 9 more · For: Thyroid Neoplasms
Sites: Fuzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression136
- death114
- diarrhoea72
- hypertension70
- fatigue68
- hypersensitivity65
- rash61
- pyrexia50
- hepatic function abnormal49
- alanine aminotransferase increased42
- aspartate aminotransferase increased42
- off label use41
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 82 |
| 2021 | 164 |
| 2022 | 214 |
| 2023 | 217 |
| 2024 | 302 |
| 2025 | 206 |
| 2026 | 210 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Retevmo (Selpercatinib)
2024 spending
$84.9M
Beneficiaries
656
4,801 claims
Per beneficiary
$129,402
$179.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,896,189 |
| 2021 | $26,343,353 |
| 2022 | $44,178,814 |
| 2023 | $57,651,230 |
| 2024 | $84,887,654 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
Zhou C, Solomon B, Loong HH, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, et al. · N Engl J Med 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Wu YL, Hochmair M, Yang Y, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V, Wolf J, Konda B, et al. · Lancet Oncol 2022 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Drilon A, Oxnard GR, Tan DSW, et al. · N Engl J Med 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.